Cargando…
Molecular pathways that drive diabetic kidney disease
Kidney disease is a major driver of mortality among patients with diabetes and diabetic kidney disease (DKD) is responsible for close to half of all chronic kidney disease cases. DKD usually develops in a genetically susceptible individual as a result of poor metabolic (glycemic) control. Molecular...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927939/ https://www.ncbi.nlm.nih.gov/pubmed/36787250 http://dx.doi.org/10.1172/JCI165654 |
_version_ | 1784888548132913152 |
---|---|
author | Mohandes, Samer Doke, Tomohito Hu, Hailong Mukhi, Dhanunjay Dhillon, Poonam Susztak, Katalin |
author_facet | Mohandes, Samer Doke, Tomohito Hu, Hailong Mukhi, Dhanunjay Dhillon, Poonam Susztak, Katalin |
author_sort | Mohandes, Samer |
collection | PubMed |
description | Kidney disease is a major driver of mortality among patients with diabetes and diabetic kidney disease (DKD) is responsible for close to half of all chronic kidney disease cases. DKD usually develops in a genetically susceptible individual as a result of poor metabolic (glycemic) control. Molecular and genetic studies indicate the key role of podocytes and endothelial cells in driving albuminuria and early kidney disease in diabetes. Proximal tubule changes show a strong association with the glomerular filtration rate. Hyperglycemia represents a key cellular stress in the kidney by altering cellular metabolism in endothelial cells and podocytes and by imposing an excess workload requiring energy and oxygen for proximal tubule cells. Changes in metabolism induce early adaptive cellular hypertrophy and reorganization of the actin cytoskeleton. Later, mitochondrial defects contribute to increased oxidative stress and activation of inflammatory pathways, causing progressive kidney function decline and fibrosis. Blockade of the renin-angiotensin system or the sodium-glucose cotransporter is associated with cellular protection and slowing kidney function decline. Newly identified molecular pathways could provide the basis for the development of much-needed novel therapeutics. |
format | Online Article Text |
id | pubmed-9927939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-99279392023-02-15 Molecular pathways that drive diabetic kidney disease Mohandes, Samer Doke, Tomohito Hu, Hailong Mukhi, Dhanunjay Dhillon, Poonam Susztak, Katalin J Clin Invest Review Kidney disease is a major driver of mortality among patients with diabetes and diabetic kidney disease (DKD) is responsible for close to half of all chronic kidney disease cases. DKD usually develops in a genetically susceptible individual as a result of poor metabolic (glycemic) control. Molecular and genetic studies indicate the key role of podocytes and endothelial cells in driving albuminuria and early kidney disease in diabetes. Proximal tubule changes show a strong association with the glomerular filtration rate. Hyperglycemia represents a key cellular stress in the kidney by altering cellular metabolism in endothelial cells and podocytes and by imposing an excess workload requiring energy and oxygen for proximal tubule cells. Changes in metabolism induce early adaptive cellular hypertrophy and reorganization of the actin cytoskeleton. Later, mitochondrial defects contribute to increased oxidative stress and activation of inflammatory pathways, causing progressive kidney function decline and fibrosis. Blockade of the renin-angiotensin system or the sodium-glucose cotransporter is associated with cellular protection and slowing kidney function decline. Newly identified molecular pathways could provide the basis for the development of much-needed novel therapeutics. American Society for Clinical Investigation 2023-02-15 /pmc/articles/PMC9927939/ /pubmed/36787250 http://dx.doi.org/10.1172/JCI165654 Text en © 2023 Mohandes et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Mohandes, Samer Doke, Tomohito Hu, Hailong Mukhi, Dhanunjay Dhillon, Poonam Susztak, Katalin Molecular pathways that drive diabetic kidney disease |
title | Molecular pathways that drive diabetic kidney disease |
title_full | Molecular pathways that drive diabetic kidney disease |
title_fullStr | Molecular pathways that drive diabetic kidney disease |
title_full_unstemmed | Molecular pathways that drive diabetic kidney disease |
title_short | Molecular pathways that drive diabetic kidney disease |
title_sort | molecular pathways that drive diabetic kidney disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927939/ https://www.ncbi.nlm.nih.gov/pubmed/36787250 http://dx.doi.org/10.1172/JCI165654 |
work_keys_str_mv | AT mohandessamer molecularpathwaysthatdrivediabetickidneydisease AT doketomohito molecularpathwaysthatdrivediabetickidneydisease AT huhailong molecularpathwaysthatdrivediabetickidneydisease AT mukhidhanunjay molecularpathwaysthatdrivediabetickidneydisease AT dhillonpoonam molecularpathwaysthatdrivediabetickidneydisease AT susztakkatalin molecularpathwaysthatdrivediabetickidneydisease |